SCHEMBL18565387

SCHEMBL18565387

Cn1c2ccccc2c2cc(-c3ccc4c(c3)[Si](c3ccccc3)(c3ccccc3)c3ccccc3-4)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
GPR3 P46089 1/20 0.41
MAPT P10636 3/20 0.40
HSD17B10 Q99714 3/20 0.40
HPGD P15428 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
NPY5R Q15761 2/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
PABPC1 P11940 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18565382 0.92 RXRA (0.47) KDM4EGPR3MAPTHSD17B10HPGD
SCHEMBL18565425 0.89 KDM4E (0.33) KDM4EMAPTHSD17B10HPGDL3MBTL1
SCHEMBL20276849 0.86 L3MBTL1 (0.45) KDM4EMAPTL3MBTL1ALDH1A1MEN1
SCHEMBL18565456 0.86 HSD17B10 (0.32) HSD17B10KMT2ARXRARXRB
SCHEMBL18566114 0.85 GPR3 (0.44) KDM4EGPR3MAPTHSD17B10HPGD
SCHEMBL18566111 0.85 GPR3 (0.44) KDM4EGPR3MAPTHSD17B10HPGD
SCHEMBL18565393 0.85 GPR3 (0.36) KDM4EGPR3MAPTHSD17B10HPGD
SCHEMBL18565392 0.85 ALKBH5 (0.41) KDM4EGPR3MAPTHSD17B10HPGD
SCHEMBL18565491 0.84 HSP90AA1 (0.31) KDM4EMAPTHSD17B10
SCHEMBL18565427 0.84 RXRA (0.37) KDM4EMAPTHSD17B10HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10290815-B2 Composition, compound, material for organic electroluminescence element, ink composition, organic electroluminescence element, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2019-05-14 US disclosed
US-20170062733-A1 COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-03-02 US disclosed
US-20170062733-A1 COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10290815-B2 Composition, compound, material for organic electroluminescence element, ink composition, organic electroluminescence element, and electronic device EED, BMI1, CD99 KDM4E 225/4885GPR3 3915/4885MAPT 1057/4885
US-20170062733-A1 COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE EED, BMI1, CD99 KDM4E 225/4885GPR3 3915/4885MAPT 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.